UK government recognises perils of reference pricing in light of new value based pricing system
This article was originally published in Scrip
The UK government says it recognises that it needs to "be careful" with regard to reference pricing as it prepares to move forward with plans for a new value based pricing system. Earl Howe, under secretary for England's department of health, has hinted that the government was considering mechanisms that would shield industry from reference pricing by allowing companies to offer discounts on the agreed value or list price.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.